ZCA
HEPA

Zeke Capital Advisors’s Hepion Pharmaceuticals HEPA Stock Holding History

Zeke Capital Advisors’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50
Closed -$99K – 321
2021
Q2 		$99K Hold
50
– – 0.01% 321
2021
Q1 		$92K Hold
50
– – 0.01% 295
2020
Q4 		$110K Buy
+50
New +$130K 0.01% 283

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AMC
Asset Management Corp Northbrook, Illinois $128M AUM 6.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Zeke Capital Advisors's HEPA Position: Q3 2021 in Review

Zeke Capital Advisors sold out of Hepion Pharmaceuticals (HEPA) in Q3 2021, closing a stake of 50 shares — an estimated $99K sold.

Zeke Capital Advisors first reported a position in HEPA in Q4 2020 and held it in 3 quarters. The position peaked at $110K in Q4 2020. 37 funds tracked by Wall St. Rank hold HEPA as of Q3 2021.

  • Zeke Capital Advisors reported no remaining Hepion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Zeke Capital Advisors sold 50 Hepion Pharmaceuticals shares in Q3 2021, an estimated $99K.
  • Zeke Capital Advisors first reported a position in Hepion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Zeke Capital Advisors's Hepion Pharmaceuticals position peaked at $110K in Q4 2020.
  • 37 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2021.

Based on Zeke Capital Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.